ZYME – zymeworks inc. (US:NASDAQ)
Stock Stats
News
FDA Approves Ziihera for HER2-Positive Biliary Tract Cancer [Yahoo! Finance]
Zymeworks Announces Participation in Upcoming Investor Conferences [Yahoo! Finance]
Zymeworks Announces Participation in Upcoming Investor Conferences
FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
Zymeworks Inc. (NYSE: ZYME) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $25.00 price target on the stock, up previously from $10.00.
Form 8-K Zymeworks Inc. For: Nov 21
Form SC 13G/A Zymeworks Inc. Filed by: Redmile Group, LLC
Form SC 13G/A Zymeworks Inc. Filed by: BIOTECHNOLOGY VALUE FUND L P
Form SC 13G Zymeworks Inc. Filed by: Rubric Capital Management LP
Form 10-Q Zymeworks Inc. For: Sep 30
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.